PROCRIT Drug Profile

Summary for Tradename: PROCRIT

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for PROCRIT

See drug prices for PROCRIT

Pharmacology for PROCRIT

Physiological Effect	Increased Erythroid Cell Production
Established Pharmacologic Class	Erythropoiesis-stimulating Agent
Chemical Structure	Erythropoietin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROCRIT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROCRIT Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2012-08-15	Company disclosures
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2013-08-20	Company disclosures
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2003-12-13	Company disclosures
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2015-05-26	Company disclosures
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2016-09-21	Company disclosures

3) Low Certainty: US Patents for PROCRIT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2033-03-11	Patent claims search
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2039-02-26	Patent claims search
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2036-04-01	Patent claims search
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2027-08-21	Patent claims search
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2039-02-26	Patent claims search
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		2039-02-26	Patent claims search

International Patents for PROCRIT

Country	Patent Number	Estimated Expiration
South Africa	849625
Australia	5272293
Canada	1341607
China	85106191
Finland	852377
Singapore	92891

Supplementary Protection Certificates for PROCRIT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB01/055	United Kingdom		PRODUCT NAME: DARBEPOETIN ALFA; REGISTERED: UK EU/1/01/185/001-030 20010608
300075	Netherlands		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
01C0050	France		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001 20010608
10199059	Germany		PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608

PROCRIT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: PROCRIT

Introduction

PROCRIT, a brand of erythropoietin (EPO) developed by Johnson & Johnson, is a biologic drug used to treat anemia associated with chronic kidney disease, HIV infection, and certain types of cancer. Here, we delve into the market dynamics and financial trajectory of PROCRIT, examining the current state, future projections, and key factors influencing its market performance.

Global Erythropoietin Drugs Market Overview

The global erythropoietin drugs market, which includes PROCRIT, was valued at USD 6.87 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 1.5% from 2023 to 2030, reaching USD 7.8 billion by 2030[1].

Market Segmentation

Type Outlook

The biologics segment, which includes PROCRIT, dominated the market with a revenue share of 55.14% in 2022. However, this segment is expected to decline over the forecast period due to the increasing penetration of biosimilars[1].

Product Outlook

Erythropoietin and darbepoetin-alfa are the primary products in this market. PROCRIT falls under the erythropoietin category, which faces competition from biosimilars and other alternative treatments.

Application Outlook

PROCRIT is primarily used in the treatment of anemia associated with chronic diseases such as cancer, renal diseases, and neurology. The cancer segment is a significant application area, but the market is also seeing growth in other areas due to increasing incidence of chronic diseases[1].

Regional Performance

North America

North America dominated the erythropoietin drugs market with a share of 40.4% in 2022. This dominance is attributed to increasing awareness about chronic diseases, favorable reimbursement policies, and the high presence of major players like Johnson & Johnson[1].

Key Players and Competition

Johnson & Johnson, the manufacturer of PROCRIT, faces competition from other major players such as Amgen, F. Hoffmann-La Roche Ltd., and biosimilar manufacturers like Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. The competitive landscape is becoming more intense with the introduction of biosimilars and alternative treatments[1].

Impact of Biosimilars

The introduction of biosimilars has significantly impacted the market dynamics of PROCRIT. Biosimilars have led to a decline in prices of biologic drugs. For instance, biologic drug prices were estimated to drop by 6.6% for branded biologics and 18.6% for the biologic-biosimilar molecule pair following exclusivity milestones[3].

Price Dynamics

The entry of biosimilars has resulted in substantial price reductions. Prices fell considerably, ranging from -21.2% to -59.3%, one year after exclusivity milestones, although the magnitude of these reductions depends on the biosimilar uptake[3].

Financial Performance of Johnson & Johnson

Johnson & Johnson, the parent company of PROCRIT, reported total revenues of $6,839 million in 2022, with product sales contributing $6,552 million. While the company's overall financial performance is robust, the specific financial trajectory of PROCRIT is influenced by the broader market trends and competition from biosimilars[5].

Future Projections and Challenges

Market Growth

Despite the overall market growth, the erythropoietin segment is expected to experience slow growth due to declining prices and increasing competition from biosimilars and alternative treatments like HIF prolyl-hydroxylase inhibitors[1].

Patent Expiry

The impending patent expiry of Aranesp in 2024 in the U.S. is another factor that could impact the market share of PROCRIT, as it may lead to increased competition from generic and biosimilar versions[1].

Key Drivers and Restraints

Drivers

• Increasing incidence of chronic diseases
• R&D activities for novel drugs
• Introduction of new erythropoietin drugs[1]

Restraints

• Declining prices due to biosimilar competition
• Patent expiries of key products
• Development and approval of alternative treatments[1]

Regional Trends

North America

The region continues to be a significant market for PROCRIT due to favorable reimbursement policies and high awareness about chronic diseases. However, the market is expected to see slower growth due to the factors mentioned above[1].

Asia Pacific

The Asia Pacific region is expected to show moderate growth driven by increasing healthcare expenditure and a growing patient population. However, the penetration of biosimilars in this region is also on the rise, which could impact PROCRIT's market share[1].

Conclusion

The market dynamics for PROCRIT are complex, influenced by the broader trends in the erythropoietin drugs market. While PROCRIT remains a significant player, the increasing competition from biosimilars, declining prices, and the development of alternative treatments pose significant challenges.

Key Takeaways

• The global erythropoietin drugs market is expected to grow at a CAGR of 1.5% from 2023 to 2030.
• The biologics segment, including PROCRIT, is losing market share due to biosimilar competition.
• North America dominates the market, but the region is expected to see slower growth.
• Increasing incidence of chronic diseases and R&D activities are key drivers, while declining prices and patent expiries are significant restraints.

FAQs

Q: What is the current market size of the global erythropoietin drugs market?

The global erythropoietin drugs market was valued at USD 6.87 billion in 2022[1].

Q: How is the market expected to grow from 2023 to 2030?

The market is expected to grow at a CAGR of 1.5% from 2023 to 2030, reaching USD 7.8 billion by 2030[1].

Q: What is the impact of biosimilars on the erythropoietin drugs market?

Biosimilars have led to significant price reductions, with biologic drug prices dropping by 6.6% for branded biologics and 18.6% for the biologic-biosimilar molecule pair following exclusivity milestones[3].

Q: Which region dominates the erythropoietin drugs market?

North America dominates the market with a share of 40.4% in 2022, driven by increasing awareness about chronic diseases and favorable reimbursement policies[1].

Q: What are the key drivers and restraints for the erythropoietin drugs market?

Key drivers include increasing incidence of chronic diseases and R&D activities, while restraints include declining prices due to biosimilar competition and patent expiries of key products[1].

Sources

1. Grand View Research: Erythropoietin Drugs Market Size & Share Report, 2030
2. ProCredit Holding: 2023 with a strong business and financial performance
3. Taylor & Francis Online: Estimating the impact of biosimilar entry on prices and expenditures
4. Transparency Market Research: Erythropoietin Drugs Market Size & Trends, Growth to 2034
5. Amgen: AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS